{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:45:00Z","timestamp":1791024300263,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: The enantiomers of the designer drugs 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethylamphetamine (MDEA) differ in their pharmacologic and toxicologic potency. The aim of this study was to develop an assay for measuring these enantiomers in small plasma volumes and to analyze samples from a controlled study with MDMA.<\/jats:p>\n               <jats:p>Methods: The analytes were extracted from \u22640.2 mL of plasma by mixed-mode solid-phase extraction. After derivatization with S-(\u2212)-heptafluorobutyrylprolyl chloride, the resulting diastereomers were separated by gas chromatography (HP-5MS) within 17 min and detected by mass spectrometry in the negative-ion chemical ionization mode. The method was fully validated and applied to samples from a controlled study in which a single dose of racemic MDMA (75 mg) was administered.<\/jats:p>\n               <jats:p>Results: The derivatized enantiomers were well separated and detected with good sensitivity. The assay was linear (per enantiomer) at 1\u201350 \u03bcg\/L for MDA and 5\u2013250 \u03bcg\/L for MDMA and MDEA. Analytical recovery, accuracy, repeatability, and intermediate precision data were within required limits. Extraction yields were 82.1%\u201395.3%. In the study samples, concentrations of R-(\u2212)-MDMA significantly exceeded those of S-(+)-MDMA. Their ratios (R vs S) were always &amp;gt;1.0 and increased over time. Concentrations of S-(+)-MDA exceeded those of R-(\u2212)-MDA, their ratios (R vs S) also increasing over time but remaining &amp;lt;1.0.<\/jats:p>\n               <jats:p>Conclusions: This assay enables sensitive, reliable, and fast enantioselective measurement of MDA, MDMA, and MDEA in small volumes of plasma. The controlled study data confirm previous findings of MDMA and MDA enantiomer ratios (R vs S) increasing over time after ingestion of racemic MDMA.<\/jats:p>","DOI":"10.1373\/clinchem.2005.052746","type":"journal-article","created":{"date-parts":[[2005,8,11]],"date-time":"2005-08-11T21:54:43Z","timestamp":1123797283000},"page":"1811-1822","source":"Crossref","is-referenced-by-count":46,"title":["Drug Testing in Blood: Validated Negative-Ion Chemical Ionization Gas Chromatographic\u2013Mass Spectrometric Assay for Enantioselective Measurement of the Designer Drugs MDEA, MDMA, and MDA and Its Application to Samples from a Controlled Study with MDMA"],"prefix":"10.1093","volume":"51","author":[{"given":"Frank T","family":"Peters","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Saarland, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Samyn","sequence":"first","affiliation":[{"name":"National Institute of Criminalistics and Criminology, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline TJ","family":"Lamers","sequence":"first","affiliation":[{"name":"Experimental Psychopharmacology Unit, Brain & Behaviour Institute, Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J","family":"Riedel","sequence":"first","affiliation":[{"name":"Experimental Psychopharmacology Unit, Brain & Behaviour Institute, Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kraemer","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Saarland, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"de Boeck","sequence":"first","affiliation":[{"name":"National Institute of Criminalistics and Criminology, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans H","family":"Maurer","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Saarland, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,10,1]]},"reference":[{"key":"2020022800561135100_R1","doi-asserted-by":"crossref","unstructured":"Hegadoren KM, Baker GB, Bourin M. 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans [Review]. Neurosci Biobehav Rev1999;23:539-553.","DOI":"10.1016\/S0149-7634(98)00046-3"},{"key":"2020022800561135100_R2","unstructured":"Kalant H. The pharmacology and toxicology of \u201cecstasy\u201d (MDMA) and related drugs [Review]. CMAJ2001;165:917-928."},{"key":"2020022800561135100_R3","doi-asserted-by":"crossref","unstructured":"de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition [Review]. Ther Drug Monit2004;26:137-144.","DOI":"10.1097\/00007691-200404000-00009"},{"key":"2020022800561135100_R4","doi-asserted-by":"crossref","unstructured":"Steele TD, McCann UD, Ricaurte GA. 3,4-Methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d): pharmacology and toxicology in animals and humans [Review]. Addiction1994;89:539-551.","DOI":"10.1111\/j.1360-0443.1994.tb03330.x"},{"key":"2020022800561135100_R5","doi-asserted-by":"crossref","unstructured":"Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs1986;:305-313.","DOI":"10.1080\/02791072.1986.10472362"},{"key":"2020022800561135100_R6","doi-asserted-by":"crossref","unstructured":"Monks TJ, Jones DC, Bai F, Lau SS. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity [Review]. Ther Drug Monit2004;26:132-136.","DOI":"10.1097\/00007691-200404000-00008"},{"key":"2020022800561135100_R7","doi-asserted-by":"crossref","unstructured":"McCann UD, Ridenour A, Shaham Y, Ricaurte GA. Serotonin neurotoxicity after (+\/\u2212)3,4-methylenedioxymethamphetamine (MDMA; \u201cEcstasy\u201d): a controlled study in humans. Neuropsychopharmacology1994;10:129-138.","DOI":"10.1038\/npp.1994.15"},{"key":"2020022800561135100_R8","doi-asserted-by":"crossref","unstructured":"McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA (\u201cEcstasy\u201d) on brain serotonin neurons in human beings. Lancet1998;352:1433-1437.","DOI":"10.1016\/S0140-6736(98)04329-3"},{"key":"2020022800561135100_R9","doi-asserted-by":"crossref","unstructured":"Moeller MR, Kraemer T. Drugs of abuse monitoring in blood for control of driving under the influence of drugs [Review]. Ther Drug Monit2002;24:210-221.","DOI":"10.1097\/00007691-200204000-00003"},{"key":"2020022800561135100_R10","doi-asserted-by":"crossref","unstructured":"Samyn N, van Haeren C. On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users. Int J Legal Med2000;113:150-154.","DOI":"10.1007\/s004140050287"},{"key":"2020022800561135100_R11","doi-asserted-by":"crossref","unstructured":"Samyn N, de Boeck G, Wood M, Lamers CTJ, De Waard D, Brookhuis KA, et al. Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Forensic Sci Int2002;128:90-97.","DOI":"10.1016\/S0379-0738(02)00157-3"},{"key":"2020022800561135100_R12","doi-asserted-by":"crossref","unstructured":"Logan BK, Couper FJ. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and driving impairment. J Forensic Sci2001;46:1426-1433.","DOI":"10.1520\/JFS15166J"},{"key":"2020022800561135100_R13","doi-asserted-by":"crossref","unstructured":"Lamers CT, Ramaekers JG, Muntjewerff ND, Sikkema KL, Samyn N, Read NL, et al. Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol2003;17:379-387.","DOI":"10.1177\/0269881103174015"},{"key":"2020022800561135100_R14","unstructured":"Riedel WJ, Lamers CTJ. A pilot study of impairment testing of MDMA with a computer-based task2000 School of Psychology, University of Leeds Leeds, United Kingdom. Project deliverable DR2b, certified EU research project (contract no RO-98-RS. 3054).."},{"key":"2020022800561135100_R15","doi-asserted-by":"crossref","unstructured":"Kraemer T, Maurer HH. Toxicokinetics of amphetamines: Metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives [Review]. Ther Drug Monit2002;24:277-289.","DOI":"10.1097\/00007691-200204000-00009"},{"key":"2020022800561135100_R16","doi-asserted-by":"crossref","unstructured":"Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ. Stereospecific analysis and enantiomeric disposition of 3,4-methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem1999;45:1058-1069.","DOI":"10.1093\/clinchem\/45.7.1058"},{"key":"2020022800561135100_R17","doi-asserted-by":"crossref","unstructured":"Pizarro N, Llebaria A, Cano S, Joglar J, Farre M, Segura J, de la Torre R. Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites by gas chromatography\/mass spectrometry. Rapid Commun Mass Spectrom2003;17:330-336.","DOI":"10.1002\/rcm.919"},{"key":"2020022800561135100_R18","unstructured":"Pizarro N, Farre M, Pujadas M, Peiro AM, Roset PN, Joglar J, de la Torre R. Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). Drug Metab Dispos2004;32:1001-1007."},{"key":"2020022800561135100_R19","doi-asserted-by":"crossref","unstructured":"Brunnenberg M, Kovar KA. Stereospecific analysis of ecstasy-like N-ethyl-3,4-methylenedioxyamphetamine and its metabolites in humans. J Chromatogr B Biomed Sci Appl2001;751:9-18.","DOI":"10.1016\/S0378-4347(00)00404-7"},{"key":"2020022800561135100_R20","doi-asserted-by":"crossref","unstructured":"Buechler J, Schwab M, Mikus G, Fischer B, Hermle L, Marx C, et al. Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci2003;793:207-222.","DOI":"10.1016\/S1570-0232(03)00266-6"},{"key":"2020022800561135100_R21","doi-asserted-by":"crossref","unstructured":"Peters FT, Kraemer T, Maurer HH. Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases. Clin Chem2002;48:1472-1485.","DOI":"10.1093\/clinchem\/48.9.1472"},{"key":"2020022800561135100_R22","doi-asserted-by":"crossref","unstructured":"Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography\/mass spectrometry. J Mass Spectrom2003;38:659-676.","DOI":"10.1002\/jms.483"},{"key":"2020022800561135100_R23","doi-asserted-by":"crossref","unstructured":"Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, et al. Bioanalytical method validation\u2014a revisit with a decade of progress. Pharm Res2000;17:1551-1557.","DOI":"10.1023\/A:1007669411738"},{"key":"2020022800561135100_R24","doi-asserted-by":"crossref","unstructured":"Massart DL, Vandeginste BGM, Buydens LMC, De Jong S, Lewi PJ, Smeyers-Verbeke J. Internal method validation. Vandeginste BGM Rutan SC eds. Handbook of chemometrics and qualimetrics: part A, 1st ed1997:379-440 Elsevier Amsterdam. .","DOI":"10.1016\/S0922-3487(98)80038-5"},{"key":"2020022800561135100_R25","unstructured":". . Evaluation of precision performance of clinical chemistry devices; approved guideline. NCCLS Document EP5-A1999 NCCLS Wayne, PA. ."},{"key":"2020022800561135100_R26","doi-asserted-by":"crossref","unstructured":"Kraemer T, Maurer HH. Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine [Review]. J Chromatogr B Biomed Sci Appl1998;713:163-187.","DOI":"10.1016\/S0378-4347(97)00515-X"},{"key":"2020022800561135100_R27","doi-asserted-by":"crossref","unstructured":"Lim HK, Hubbard JW, Midha KK. Development of enantioselective gas chromatographic quantitation assay for dl-threo-methylphenidate in biological fluids. J Chromatogr1986;378:109-123.","DOI":"10.1016\/S0378-4347(00)80704-5"},{"key":"2020022800561135100_R28","doi-asserted-by":"crossref","unstructured":"de Boer D, Tan LP, Gorter P, van-de-Wal RM, Kettenes-van den, Bosch JJ, de-Bruijn EA, et al. Gas chromatographic\/mass spectrometric assay for profiling the enantiomers of 3,4-methylenedioxymethamphetamine and its chiral metabolites using positive chemical ionization ion trap mass spectrometry. J Mass Spectrom1997;32:1236-1246.","DOI":"10.1002\/(SICI)1096-9888(199711)32:11<1236::AID-JMS584>3.0.CO;2-K"},{"key":"2020022800561135100_R29","doi-asserted-by":"crossref","unstructured":"Lim HK, Su Z, Foltz RL. Stereoselective disposition: enantioselective quantitation of 3,4-(methylenedioxy) methamphetamine and three of its metabolites by gas chromatography\/electron capture negative ion chemical ionization mass spectrometry. Biol Mass Spectrom1993;22:403-411.","DOI":"10.1002\/bms.1200220707"},{"key":"2020022800561135100_R30","doi-asserted-by":"crossref","unstructured":"Segura J, Ventura R, Jurado C. Derivatization procedures for gas chromatographic-mass spectrometric determination of xenobiotics in biological samples, with special attention to drugs of abuse and doping agents [Review]. J Chromatogr B1998;713:61-90.","DOI":"10.1016\/S0378-4347(98)00089-9"},{"key":"2020022800561135100_R31","doi-asserted-by":"crossref","unstructured":"Srinivas NR, Hubbard JW, Cooper JK, Midha KK. Enantioselective gas chromatographic assay with electron-capture detection for dl-fenfluramine and dl-norfenfluramine in plasma. J Chromatogr1988;433:105-117.","DOI":"10.1016\/S0378-4347(00)80589-7"},{"key":"2020022800561135100_R32","doi-asserted-by":"crossref","unstructured":"Srinivas NR, Hubbard JW, Hawes EM, McKay G, Midha KK. Enantioselective gas chromatographic assays with electron-capture detection for methoxyphenamine and its three primary metabolites in human urine. J Chromatogr1989;487:61-72.","DOI":"10.1016\/S0378-4347(00)83007-8"},{"key":"2020022800561135100_R33","doi-asserted-by":"crossref","unstructured":"Maurer HH. The role of gas chromatography-mass spectrometry with negative ion chemical ionization (GC-MS-NCI) in cinical and forensic toxicology, doping control and biomonitoring [Review]. Ther Drug Monit2002;24:247-254.","DOI":"10.1097\/00007691-200204000-00007"},{"key":"2020022800561135100_R34","doi-asserted-by":"crossref","unstructured":"Wieling J, Hendriks G, Tamminga WJ, Hempenius J, Mensink CK, Oosterhuis B, et al. Rational experimental design for bioanalytical methods validation. Illustration using an assay method for total captopril in plasma. J Chromatogr A1996;730:381-394.","DOI":"10.1016\/0021-9673(96)00006-4"},{"key":"2020022800561135100_R35","doi-asserted-by":"crossref","unstructured":"Peters FT, Samyn N, Kraemer T, de Boeck G, Maurer HH. Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. J Anal Toxicol2003;27:552-559.","DOI":"10.1093\/jat\/27.8.552"},{"key":"2020022800561135100_R36","doi-asserted-by":"crossref","unstructured":"Hartmann C, Smeyers-Verbeke J, Massart DL, McDowall RD. Validation of bioanalytical chromatographic methods [Review]. J Pharm Biomed Anal1998;17:193-218.","DOI":"10.1016\/S0731-7085(97)00198-2"},{"key":"2020022800561135100_R37","doi-asserted-by":"crossref","unstructured":"Peters FT, Maurer HH. Bioanalytical method validation and its implications for forensic and clinical toxicology\u2014a review [Review]. Accred Qual Assur2002;7:441-449.","DOI":"10.1007\/s00769-002-0516-5"},{"key":"2020022800561135100_R38","doi-asserted-by":"crossref","unstructured":"Clauwaert KM, Van Bocxlaer JF, De Leenheer AP. Stability study of the designer drugs \u201cMDA, MDMA and MDEA\u201d in water, serum, whole blood, and urine under various storage temperatures. Forensic Sci Int2001;124:36-42.","DOI":"10.1016\/S0379-0738(01)00562-X"},{"key":"2020022800561135100_R39","doi-asserted-by":"crossref","unstructured":"de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, et al. Non-linear pharmacokinetics of MDMA (\u2018ecstasy\u2019) in humans. Br J Clin Pharmacol2000;49:104-109.","DOI":"10.1046\/j.1365-2125.2000.00121.x"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/51\/10\/1811\/32684631\/clinchem1811.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/51\/10\/1811\/32684631\/clinchem1811.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T01:00:48Z","timestamp":1582851648000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/51\/10\/1811\/5629489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2005,10,1]]},"published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2005.052746","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,10,1]]},"published":{"date-parts":[[2005,10,1]]}}}